This article is more than 5 years old. Information may no longer be current.
VIDEO: SOLID-TIMI 52 substudy shows IL-6 independently predicts CV outcomes
CHICAGO — Christina L. Fanola, MD, a vascular cardiologist and clinical researcher with the TIMI Study Group at the Brigham and Women’s Hospital and Harvard Medical School in Boston, discusses lessons on inflammation and CV disease at the annual ACC Scientific Session.
After offering background on the “complex process” of ACS and highlighting research gaps, she provides a brief overview of the randomized SOLID-TIMI 52 trial investigating the Lp-PLA2 inhibitor darapladib (GlaxoSmithKline) and describes a biomarker sub-study looking at the associations between IL-6 levels and MACE, CV death and HF hospitalization.
“Our study concluded that IL-6 is a significant independent predictor of CV outcomes in ACS,” she said.
She notes that research into the use of inflammatory biomarkers as therapeutic targets in ACS and vascular disease is ongoing, pointing to both the Cardiovascular Inflammation Reduction Trial, or CIRT trial, and the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study, or CANTOS study.